Brought to you by 
Almirall to acquire products from Allergan's US medical dermatology portfolio; finalizes deal for up to $650mm
27 May 2021
Executive Summary
Almirall SA agreed to acquire a portfolio of four products and one late-phase compound from Allergan PLC's US medical dermatology unit, a part of the Irish company's US specialized therapeutics business segment.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Topical Delivery
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Almirall to acquire products from Allergan's US medical dermatology portfolio; finalizes deal for up to $650mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice